JP2016501223A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501223A5
JP2016501223A5 JP2015545193A JP2015545193A JP2016501223A5 JP 2016501223 A5 JP2016501223 A5 JP 2016501223A5 JP 2015545193 A JP2015545193 A JP 2015545193A JP 2015545193 A JP2015545193 A JP 2015545193A JP 2016501223 A5 JP2016501223 A5 JP 2016501223A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015545193A
Other languages
English (en)
Japanese (ja)
Other versions
JP6382831B2 (ja
JP2016501223A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/072064 external-priority patent/WO2014085489A1/en
Publication of JP2016501223A publication Critical patent/JP2016501223A/ja
Publication of JP2016501223A5 publication Critical patent/JP2016501223A5/ja
Application granted granted Critical
Publication of JP6382831B2 publication Critical patent/JP6382831B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015545193A 2012-11-30 2013-11-26 アポトーシス阻害タンパク質(iap)のアンタゴニスト Active JP6382831B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261731794P 2012-11-30 2012-11-30
US61/731,794 2012-11-30
PCT/US2013/072064 WO2014085489A1 (en) 2012-11-30 2013-11-26 Inhibitor of apoptosis protein (iap) antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018101004A Division JP2018162256A (ja) 2012-11-30 2018-05-25 アポトーシス阻害タンパク質(iap)のアンタゴニスト

Publications (3)

Publication Number Publication Date
JP2016501223A JP2016501223A (ja) 2016-01-18
JP2016501223A5 true JP2016501223A5 (enExample) 2016-12-15
JP6382831B2 JP6382831B2 (ja) 2018-08-29

Family

ID=50828427

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015545193A Active JP6382831B2 (ja) 2012-11-30 2013-11-26 アポトーシス阻害タンパク質(iap)のアンタゴニスト
JP2018101004A Pending JP2018162256A (ja) 2012-11-30 2018-05-25 アポトーシス阻害タンパク質(iap)のアンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018101004A Pending JP2018162256A (ja) 2012-11-30 2018-05-25 アポトーシス阻害タンパク質(iap)のアンタゴニスト

Country Status (5)

Country Link
US (5) US9546174B2 (enExample)
EP (1) EP2925764B1 (enExample)
JP (2) JP6382831B2 (enExample)
CA (1) CA2896577C (enExample)
WO (1) WO2014085489A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2896577C (en) 2012-11-30 2024-01-23 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (iap) antagonists
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
JP6768522B2 (ja) 2014-06-04 2020-10-14 サンフォード−バーンハム メディカル リサーチ インスティテュート Hiv治療におけるアポトーシスタンパク質阻害剤(iap)のアンタゴニストの使用
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
CN113613724B (zh) * 2018-11-30 2024-11-08 葛兰素史克知识产权开发有限公司 可用于hiv疗法的化合物
EP3911316A1 (en) 2019-01-17 2021-11-24 Debiopharm International SA Combination product for the treatment of cancer
CN110028508B (zh) * 2019-05-16 2021-05-28 南京华威医药科技集团有限公司 一种抗肿瘤的重氮双环类细胞凋亡蛋白抑制剂
US12636370B2 (en) 2019-08-08 2026-05-26 Institute For Cancer Research Combination therapy for treatment of cancer
AU2020356356A1 (en) 2019-09-25 2022-05-12 Debiopharm International S.A. Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
US12678509B2 (en) 2019-11-08 2026-07-14 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (IAP) protein antagonists
EP4143198A4 (en) * 2020-04-30 2024-05-01 Sanford Burnham Prebys Medical Discovery Institute INHIBITOR OF APOPTOSIS PROTEIN ANTAGONISTS (API)
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
US20250129099A1 (en) * 2021-11-04 2025-04-24 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (iap) protein antagonists
AR131299A1 (es) * 2022-12-09 2025-03-05 Debiopharm Int Sa Nuevos inhibidores de iap, métodos para fabricarlos y usos de los mismos
AU2024367811A1 (en) * 2023-10-24 2026-05-07 Tract Pharmaceuticals, Inc. Combination of iap inhibitors and cellular kinase inhibitors, such as ponatinib, for use in the treatment of cancer or pulmonary diseases, such as copd, cystic fibrosis, pulmonary fibrosis and covid-19

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5455242A (en) 1991-09-27 1995-10-03 Merrell Dow Pharmaceuticals Inc. Carboxyalkyl tricyclic derivatives useful as inhibitors of enkephalinase and ace
US5457196A (en) 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
PT669936E (pt) 1992-10-30 2001-04-30 Merrell Pharma Inc Derivados de lactama biciclica de mercaptoacetilamida uteis como inibidores de encefalinase e de ace
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
FR2803594B1 (fr) * 2000-01-11 2002-07-19 Centre Nat Rech Scient Oligomeres de mimes contraints non peptidiques de dipeptides ou de tripeptides, et leurs utilisations
BRPI0506883A (pt) * 2004-01-16 2007-05-29 Univ Michigan miméticos de smac conformacionalmente comprimidos e seus usos
KR100926203B1 (ko) 2004-07-02 2009-11-09 제넨테크, 인크. Iap의 억제제
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
BRPI0513310A (pt) * 2004-07-12 2008-05-06 Idun Pharmaceuticals Inc análogos de tetrapeptìdeo
AU2006255084A1 (en) * 2005-06-08 2006-12-14 Novartis Ag Organic compounds
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
US20090010941A1 (en) 2007-04-09 2009-01-08 University Of Massachusetts Methods for treating HIV
WO2008128171A2 (en) 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
US8445473B2 (en) 2008-04-11 2013-05-21 The Regents Of The University Of Michigan Heteroaryl-substituted bicyclic Smac mimetics and the uses thereof
JP2010174138A (ja) 2009-01-29 2010-08-12 Nok Kluber Kk グリース組成物の製造方法及び該方法により製造されるグリース組成物
US8642544B2 (en) * 2009-04-01 2014-02-04 Amylin Pharmaceuticals, Llc N-terminus conformationally constrained GLP-1 receptor agonist compounds
US9346852B2 (en) 2011-03-14 2016-05-24 Bristol-Myers Scuibb Company Substituted adipic acid amides and uses thereof
US20150174235A1 (en) 2012-06-06 2015-06-25 Bionor Immuno As Vaccine
CA2896577C (en) 2012-11-30 2024-01-23 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (iap) antagonists
JP6768522B2 (ja) 2014-06-04 2020-10-14 サンフォード−バーンハム メディカル リサーチ インスティテュート Hiv治療におけるアポトーシスタンパク質阻害剤(iap)のアンタゴニストの使用

Similar Documents

Publication Publication Date Title
JP2009536620A5 (enExample)
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
RU2016110096A (ru) Новое хинолин-замещенное соединение
JP2017522273A5 (enExample)
RU2011108281A (ru) Трипиридилкарбоксамидные антагонисты орексиновых рецепторов
JP2015537008A5 (enExample)
RU2016150404A (ru) Пирроло[2,3-с]пиридины в качестве визуализирующих агентов для нейрофибриллярных клубков
RU2015141592A (ru) АРИЛ-СУЛЬФАМИДЫ И СУЛЬФАМАТЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORc
JP2015143283A5 (enExample)
JP2013510178A5 (enExample)
JP2014510727A5 (enExample)
RU2013123790A (ru) Ингибиторы cdk
JP2014511892A5 (enExample)
JP2013519684A5 (enExample)
RU2016126503A (ru) Аналоги кортистатина, их синтез и применения
JP2021534108A5 (enExample)
ME02558B (me) Inhibitori replikacije virusa gripa
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
AR076550A1 (es) Inhibidores de la janus tirosina kinasa (jak)
JP2013510120A5 (enExample)
JP2016513130A5 (enExample)
HRP20220479T1 (hr) Spojevi
JP2015521195A5 (enExample)
JP2017501237A5 (enExample)
JP2016506962A5 (enExample)